tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Valneva’s Chikungunya Vaccine IXCHIQ® Resumes Use for Elderly After FDA Approval

Story Highlights
  • Valneva’s chikungunya vaccine IXCHIQ® is now approved for use in individuals 60 and older.
  • The FDA updated IXCHIQ®’s prescribing information due to serious adverse events in elderly.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Valneva’s Chikungunya Vaccine IXCHIQ® Resumes Use for Elderly After FDA Approval

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Valneva ( (VALN) ).

On August 7, 2025, Valneva announced that the FDA has lifted its recommended pause on the use of the chikungunya vaccine IXCHIQ® for individuals aged 60 and older, following a comprehensive review by the European Medicines Agency. The prescribing information for IXCHIQ® has been updated to reflect reports of serious adverse events, particularly in elderly individuals with multiple underlying health conditions. This decision allows the vaccine to remain available for high-risk individuals aged 18 and older, although it is not recommended for most U.S. travelers due to low risk of exposure. The FDA is also reviewing potential label extensions for adolescents and additional persistence data.

The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s stock score is primarily influenced by financial challenges and valuation concerns. However, strong technical performance and promising earnings call developments provide a counterbalance. The most impactful factors include negative financial metrics and a potential overvaluation, moderated by current market momentum and strategic achievements.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is involved in developing vaccine candidates against Lyme disease, Zika virus, and other global public health threats.

Average Trading Volume: 48,557

Technical Sentiment Signal: Buy

Current Market Cap: $667.4M

Learn more about VALN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1